Passionate about treating (and curing) #HFrEF #HFpEF #HCM and #AMYLOIDOSIS. Research is the path forward. Opinions are my own entirely.
Joined May 2018
- Tweets 773
- Following 339
- Followers 587
- Likes 1,119
94 Photos and videos
Stephen Heitner retweeted
13 Mar 2023
New article published today by @ClaraMosq on new #MachineLearning #algorithm to automatically detect meals and estimate size of meal for use within fully automated insulin delivery for people with #T1D
nature.com/articles/s41746-0…
7
17
1,071
12 Mar 2023
I have a small request for my medical and paramedical colleagues - please can you take 20 seconds from your day and complete this brief survey. I’m hoping to bring something special to medical practitioners in the furniture….thanks much!
forms.gle/h4jxeStLDp4ynVdr6
1
1
5
1,073
Stephen Heitner retweeted
10 Jan 2023
2023 is our 25th year as a company, a momentous milestone that marks a quarter century of our devotion to science & to patients.
We'll be celebrating our 25th by sharing the moments & people that have made us into the company we are today. #Cyto25
bit.ly/3XbMOcq
2
8
666
1 Dec 2022
Thanks @nytimes for being my top podcast on @Spotify this year. I loved all 458 minutes of it. #SpotifyWrapped open.spotify.com/show/3IM0lm…
Stephen Heitner retweeted
24 Nov 2022
#HappyThanksgiving from all of us at Cytokinetics!
We’re #thankful for a lot, but we’re especially thankful for our amazing team of employees who work hard every day toward our collective goal of improving the lives of patients with diseases of impaired muscle function.
1
5
Stephen Heitner retweeted
22 Nov 2022
So proud of our #HCM team and our patients. We just evaluated our 50th patient for aficamten, a cardiac myosin inhibitor. & we had a cake with asymmetrical septal hypertrophy, a myectomy and a sarcomere unit - made by the brilliant MLL ( instagram.com/hapagirlcakes/ )
#CardioTwitter
8
5
79
Stephen Heitner retweeted
15 Nov 2022
A few weeks ago, we hosted our first annual Cytokinetics Research Day. It was a jam-packed day with excellent presentations from our colleagues in research showcasing their work. We loved taking a dive into the innovative research taking place that powers our continued progress.
1
1
7
Stephen Heitner retweeted
25 Oct 2022
Last week we hosted Jillian, a member of our #HCM Patient & Caregiver Advisory Council, at our SSF office. While onsite, Jillian saw firsthand how she & others like her inspire us to do the work that we do. Learn more about HCM and Jillian’s journey here: bit.ly/3DuGmGi
3
9
Stephen Heitner retweeted
7 Sep 2022
We are excited to announce that we have been recognized as one of @FortuneMagazine's Best Workplaces in BioPharma in 2022! #BestWorkplaces
We are honored to be a best workplace & are grateful to our wonderful Cytokinetics team. bit.ly/3cU1xqM
3
13
Stephen Heitner retweeted
3 Sep 2022
Our paper on the first-in-human study of #aficamten is out with an editorial by Zoltan Papp - thanks to all those that contributed! We are now studying #aficamten in a Phase 3 clinical trial, #SEQUOIAHCM. Privileged to work with wonderful collaborators worldwide #teamwork.
30 Aug 2022
In this #JACCBTS clinical case, authors examine the efficacy, safety, ease of use, pharmacokinetic, and pharmacodynamic of aficamten. bit.ly/3pWPg7T
#cvHCM #openaccess #BasicResearch #TranslationalResearch #CardioTwitter @MyosinMD @scottdsolomon
9
31
Stephen Heitner retweeted
18 Aug 2022
Join us in donating to the @YoseConservancy to protect sequoias threatened by wildfires across CA. Sequoias were chosen as the namesake of our Phase 3 clinical trial SEQUOIA-HCM because they help convey strength and resilience. Learn more here: bit.ly/3QNlFcw
3
7
Stephen Heitner retweeted
22 Jul 2022
Omecamtiv mecarbil joins bblck, SGLT2i, ARNI, ACE/ARB, MRA as HFrEF pharmacotherapies that improve clin outcomes but not exercise capacity in RCTs. It was an honor to work w/@DukeHFDoc & the entire METEORIC-HF team to rigorously conduct this trial. @MGHHeartHealth @MGHMedicine
20 Jul 2022
#OriginalInvestigation: Multicenter randomized clinical trial found that, in patients with chronic #HFrEF, omecamtiv mecarbil did not significantly improve exercise capacity over 20 weeks compared with placebo. @GLewisCardiol ja.ma/3zebwjc
9
37
Stephen Heitner retweeted
21 Jul 2022
The @hcmsociety inaugural scientific sessions will take place on Friday 9/30 in DC
Join us ( @HFSA )
Register here and consider becoming a member
hcmsociety.org/Membership
Abstracts website is now open
auth.oxfordabstracts.com/?re…
#CardioTwitter #HCM
20 Jul 2022
For the past year we’ve been working on the birth of a new medical society - HCMS!
education, awareness, research and collaboration
Join us 9/30 adjoining @HFSA and become a member. @4hcm @HCMBeat @LindsayLuvDavis @CSHeartResearch @AnkurKalraMD @purviparwani @mmartinezheart
5
7
Stephen Heitner retweeted
21 Jul 2022
HCM Society Inaugural Scientific Sessions - Sep 30th 2022 - SAVE THE DATE and register early! Inaugural Keynote by Dr. Eugene BRAUNWALD - be there and witness history!!! @hcmsociety
Great news! Announcing the launch of the Hypertrophic Cardiomyopathy Medical Society Inaugural Scientific Sessions. Learn more at hcmsociety.org
#hypertrophiccardiomyopathy #FightHeartDisease
3
9
Stephen Heitner retweeted
15 Jun 2022
We are excited to announce that we have been recognized as one of @FortuneMagazine’s Best Workplaces in the Bay Area in 2022! #100BestCos
Thank you to our wonderful team for making Cytokinetics such a great place to work.
bit.ly/3OlWZa1
4
7
Stephen Heitner retweeted
12 Jun 2022
Presented at #ASE2022 by Ted Abraham, #echofirst findings from the 10-week on treatment placebo-controlled phase II aficamten in obstructive #HCM (#REDWOOD-HCM). Follow along if you've missed the #ASE2022 presentation
#CardioTwitter
4
16
36
Stephen Heitner retweeted
26 May 2022
Here's today's Imaging Wire bit.ly/IW_421
Featuring... @ultromics @Rad_Partners @ARAImaging @radai @FujifilmHealth @annalise_ai @ButterflyNetInc @enlitic @histosonics @GEHealthcare @aidocmed @gleamer_ai @RapidAI @DrRossUpton @JODriscoll9 @malsharqi1 @HeitnerStephen
1
3
10
Stephen Heitner retweeted
23 May 2022
Significant reduction in NTproBNP and hsTnI which are favorable to see in #HCM
2
1
1
Stephen Heitner retweeted
23 May 2022
Significant improvement in NYHA class by 12 and 24 weeks, where ~80% of patients had improvement by 1 NYHA class or more. No worsening in NYHA class, and 21% remained in the same NYHA class (typically class II).
1
1